Rivaroxaban vs Apixaban and Major Ischemic or Hemorrhagic Events in Patients With AF | Atrial Fibrillation | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation

Educational Objective
To understand the comparative effectiveness of oral anticoagulants for ischemic stroke prevention in patients with atrial fibrillation.
1 Credit CME
Key Points

Question  Is there a difference in risk of major ischemic or hemorrhagic events in patients with atrial fibrillation treated with rivaroxaban vs apixaban?

Findings  In this retrospective cohort study that included 581 451 patients 65 years or older enrolled in Medicare with atrial fibrillation, the adjusted incidence of major ischemic or hemorrhagic events was 16.1 per 1000 person-years for rivaroxaban vs 13.4 per 1000 person-years for apixaban, a difference that was statistically significant.

Meaning  Among older adults with atrial fibrillation, treatment with rivaroxaban compared with apixaban was associated with a significantly increased risk of major ischemic or hemorrhagic events.

Abstract

Importance  The comparative effectiveness of rivaroxaban and apixaban, the most frequently prescribed oral anticoagulants for ischemic stroke prevention in patients with atrial fibrillation, is uncertain.

Objective  To compare major ischemic and hemorrhagic outcomes in patients with atrial fibrillation treated with rivaroxaban or apixaban.

Design, Setting, and Participants  Retrospective cohort study using computerized enrollment and claims files for US Medicare beneficiaries 65 years or older. Between January 1, 2013, and November 30, 2018, a total of 581 451 patients with atrial fibrillation began rivaroxaban or apixaban treatment and were followed up for 4 years, through November 30, 2018.

Exposures  Rivaroxaban (n = 227 572) and apixaban (n = 353 879), either standard or reduced dose.

Main Outcomes and Measures  The primary outcome was a composite of major ischemic (stroke/systemic embolism) and hemorrhagic (intracerebral hemorrhage/other intracranial bleeding/fatal extracranial bleeding) events. Secondary outcomes were nonfatal extracranial bleeding and total mortality (fatal ischemic/hemorrhagic event or other death during follow-up). Rates, hazard ratios (HRs), and rate differences (RDs) were adjusted for baseline differences in comorbidity with inverse probability of treatment weighting.

Results  Study patients (mean age, 77.0 years; 291 966 [50.2%] women; 134 393 [23.1%] receiving reduced dose) had 474 605 person-years of follow-up (median [IQR] of 174 [62-397] days). The adjusted primary outcome rate for rivaroxaban was 16.1 per 1000 person-years vs 13.4 per 1000 person-years for apixaban (RD, 2.7 [95% CI, 1.9-3.5]; HR, 1.18 [95% CI, 1.12-1.24]). The rivaroxaban group had increased risk for both major ischemic events (8.6 vs 7.6 per 1000 person-years; RD, 1.1 [95% CI, 0.5-1.7]; HR, 1.12 [95% CI, 1.04-1.20]) and hemorrhagic events (7.5 vs 5.9 per 1000 person-years; RD, 1.6 [95% CI, 1.1-2.1]; HR, 1.26 [95% CI, 1.16-1.36]), including fatal extracranial bleeding (1.4 vs 1.0 per 1000 person-years; RD, 0.4 [95% CI, 0.2-0.7]; HR, 1.41 [95% CI, 1.18-1.70]). Patients receiving rivaroxaban had increased risk of nonfatal extracranial bleeding (39.7 vs 18.5 per 1000 person-years; RD, 21.1 [95% CI, 20.0-22.3]; HR, 2.07 [95% CI, 1.99-2.15]), fatal ischemic/hemorrhagic events (4.5 vs 3.3 per 1000 person-years; RD, 1.2 [95% CI, 0.8-1.6]; HR, 1.34 [95% CI, 1.21-1.48]), and total mortality (44.2 vs 41.0 per 1000 person-years; RD, 3.1 [95% CI, 1.8-4.5]; HR, 1.06 [95% CI, 1.02-1.09]). The risk of the primary outcome was increased for rivaroxaban in both those receiving the reduced dose (27.4 vs 21.0 per 1000 person-years; RD, 6.4 [95% CI, 4.1-8.7]; HR, 1.28 [95% CI, 1.16-1.40]) and the standard dose (13.2 vs 11.4 per 1000 person-years; RD, 1.8 [95% CI, 1.0-2.6]; HR, 1.13 [95% CI, 1.06-1.21]) groups.

Conclusions and Relevance  Among Medicare beneficiaries 65 years or older with atrial fibrillation, treatment with rivaroxaban compared with apixaban was associated with a significantly increased risk of major ischemic or hemorrhagic events.

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Wayne A. Ray, PhD, Department of Health Policy, 2525 West End Ave, Room 717, Nashville, TN 37203 (wayne.ray@vumc.org).

Accepted for Publication: November 8, 2021.

Author Contributions: Dr Ray had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Ray, Chung, Stein, Smalley, Zimmerman, Hung, Murray.

Acquisition, analysis, or interpretation of data: Ray, Chung, Stein, Zimmerman, Dupont, Daugherty, Dickson, Murray.

Drafting of the manuscript: Ray, Dickson, Murray.

Critical revision of the manuscript for important intellectual content: Ray, Chung, Stein, Smalley, Zimmerman, Dupont, Hung, Daugherty, Murray.

Statistical analysis: Ray, Zimmerman, Dupont.

Obtained funding: Ray.

Administrative, technical, or material support: Ray, Chung, Zimmerman, Hung, Daugherty, Dickson, Murray.

Supervision: Ray.

Conflict of Interest Disclosures: Dr Ray reported receiving grants from the National Heart, Lung, and Blood Institute (NHLBI) during the conduct of the study. Dr Chung reported receiving grants from the National Institutes of Health and grants from Veterans Affairs during the conduct of the study. Mr Daugherty reported receiving grants from NHLBI during the conduct of the study. Dr Hung reported receiving grants from Veterans Affairs during the conduct of the study. Dr Murray reported a patent pending with Vanderbilt University Medical Center from Metabolic Technologies outside the submitted work. No other disclosures were reported.

Funding/Support: The study was supported by a grant from the NHLBI (#HL151523). Access to study data was provided by the Virtual Research Data Center of the Centers for Medicare & Medicaid Services.

Role of the Funder/Sponsor: The funder had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

References
1.
Kornej  J , Börschel  CS , Benjamin  EJ , Schnabel  RB .  Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights.   Circ Res. 2020;127(1):4-20. doi:10.1161/CIRCRESAHA.120.316340PubMedGoogle ScholarCrossref
2.
Zimetbaum  P .  Atrial fibrillation.   Ann Intern Med. 2017;166(5):ITC33-ITC48. doi:10.7326/AITC201703070PubMedGoogle ScholarCrossref
3.
January  CT , Wann  LS , Calkins  H ,  et al.  2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in collaboration with the Society of Thoracic Surgeons.   Circulation. 2019;140(2):e125-e151. doi:10.1161/CIR.0000000000000665PubMedGoogle ScholarCrossref
4.
Zhu  J , Alexander  GC , Nazarian  S , Segal  JB , Wu  AW .  Trends and variation in oral anticoagulant choice in patients with atrial fibrillation, 2010-2017.   Pharmacotherapy. 2018;38(9):907-920. doi:10.1002/phar.2158PubMedGoogle ScholarCrossref
5.
Gong  IY , Kim  RB .  Importance of pharmacokinetic profile and variability as determinants of dose and response to dabigatran, rivaroxaban, and apixaban.   Can J Cardiol. 2013;29(7)(suppl):S24-S33. doi:10.1016/j.cjca.2013.04.002PubMedGoogle ScholarCrossref
6.
Reilly  PA , Lehr  T , Haertter  S ,  et al; RE-LY Investigators.  The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY trial (randomized evaluation of long-term anticoagulation therapy).   J Am Coll Cardiol. 2014;63(4):321-328. doi:10.1016/j.jacc.2013.07.104PubMedGoogle ScholarCrossref
7.
Ruff  CT , Giugliano  RP , Braunwald  E ,  et al.  Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.   Lancet. 2015;385(9984):2288-2295. doi:10.1016/S0140-6736(14)61943-7PubMedGoogle ScholarCrossref
8.
Frost  C , Song  Y , Barrett  YC ,  et al.  A randomized direct comparison of the pharmacokinetics and pharmacodynamics of apixaban and rivaroxaban.   Clin Pharmacol. 2014;6:179-187. doi:10.2147/CPAA.S61131PubMedGoogle Scholar
9.
Graham  DJ , Reichman  ME , Wernecke  M ,  et al.  Stroke, bleeding, and mortality risks in elderly Medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation.   JAMA Intern Med. 2016;176(11):1662-1671. doi:10.1001/jamainternmed.2016.5954PubMedGoogle ScholarCrossref
10.
Welcome to the Chronic Conditions Data Warehouse. Centers for Medicare & Medicaid Services. Accessed May 13, 2021. https://www2.ccwdata.org/web/guest/home/
11.
 Which oral anticoagulant for atrial fibrillation.   Med Lett Drugs Ther. 2016;58(1492):45-46.PubMedGoogle Scholar
12.
Ray  WA .  Evaluating medication effects outside of clinical trials: new-user designs.   Am J Epidemiol. 2003;158(9):915-920. doi:10.1093/aje/kwg231PubMedGoogle ScholarCrossref
13.
Ezekowitz  MD , Aikens  TH , Nagarakanti  R , Shapiro  T .  Atrial fibrillation: outpatient presentation and management.   Circulation. 2011;124(1):95-99. doi:10.1161/CIRCULATIONAHA.110.967455PubMedGoogle ScholarCrossref
14.
Sherwood  MW , Nessel  CC , Hellkamp  AS ,  et al.  Gastrointestinal bleeding in patients with atrial fibrillation treated with rivaroxaban or warfarin: ROCKET AF trial.   J Am Coll Cardiol. 2015;66(21):2271-2281. doi:10.1016/j.jacc.2015.09.024PubMedGoogle ScholarCrossref
15.
Graham  DJ , Baro  E , Zhang  R ,  et al.  Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation.   Am J Med. 2019;132(5):596-604.e11. doi:10.1016/j.amjmed.2018.12.023PubMedGoogle ScholarCrossref
16.
Chang  TE , Tong  X , George  MG ,  et al; Paul Coverdell National Acute Stroke Program team.  Trends and factors associated with concordance between International Classification of Diseases, Ninth and Tenth Revision, clinical modification codes and stroke clinical diagnoses.   Stroke. 2019;50(8):1959-1967. doi:10.1161/STROKEAHA.118.024092PubMedGoogle ScholarCrossref
17.
Hsieh  MT , Hsieh  CY , Tsai  TT , Wang  YC , Sung  SF .  Performance of ICD-10-CM diagnosis codes for identifying acute ischemic stroke in a national health insurance claims database.   Clin Epidemiol. 2020;12:1007-1013. doi:10.2147/CLEP.S273853PubMedGoogle ScholarCrossref
18.
Cunningham  A , Stein  CM , Chung  CP , Daugherty  JR , Smalley  WE , Ray  WA .  An automated database case definition for serious bleeding related to oral anticoagulant use.   Pharmacoepidemiol Drug Saf. 2011;20(6):560-566. doi:10.1002/pds.2109PubMedGoogle ScholarCrossref
19.
Ray  WA , Chung  CP , Murray  KT ,  et al.  Association of oral anticoagulants and proton pump inhibitor cotherapy with hospitalization for upper gastrointestinal tract bleeding.   JAMA. 2018;320(21):2221-2230. doi:10.1001/jama.2018.17242PubMedGoogle ScholarCrossref
20.
Arnason  T , Wells  PS , van Walraven  C , Forster  AJ .  Accuracy of coding for possible warfarin complications in hospital discharge abstracts.   Thromb Res. 2006;118(2):253-262. doi:10.1016/j.thromres.2005.06.015PubMedGoogle ScholarCrossref
21.
Fralick  M , Colacci  M , Schneeweiss  S , Huybrechts  KF , Lin  KJ , Gagne  JJ .  Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study.   Ann Intern Med. 2020;172(7):463-473. doi:10.7326/M19-2522PubMedGoogle ScholarCrossref
22.
Lip  GYH , Keshishian  A , Li  X ,  et al.  Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients.   Stroke. 2018;49(12):2933-2944. doi:10.1161/STROKEAHA.118.020232PubMedGoogle ScholarCrossref
23.
Simard  M , Sirois  C , Candas  B .  Validation of the combined comorbidity index of Charlson and Elixhauser to predict 30-day mortality across ICD-9 and ICD-10.   Med Care. 2018;56(5):441-447. doi:10.1097/MLR.0000000000000905PubMedGoogle ScholarCrossref
24.
Kim  DH , Schneeweiss  S , Glynn  RJ , Lipsitz  LA , Rockwood  K , Avorn  J .  Measuring frailty in Medicare data: development and validation of a claims-based frailty index.   J Gerontol A Biol Sci Med Sci. 2018;73(7):980-987. doi:10.1093/gerona/glx229PubMedGoogle ScholarCrossref
25.
Dzeshka  MS , Lane  DA , Lip  GY .  Stroke and bleeding risk in atrial fibrillation: navigating the alphabet soup of risk-score acronyms (CHADS2, CHA2 DS2 -VASc, R2 CHADS2, HAS-BLED, ATRIA, and more).   Clin Cardiol. 2014;37(10):634-644. doi:10.1002/clc.22294PubMedGoogle ScholarCrossref
26.
Chen  PC , Lip  GY , Yeh  G , Lin  HJ , Chien  KL .  Risk of bleeding and stroke with oral anticoagulation and antiplatelet therapy in patients with atrial fibrillation in Taiwan: a nationwide cohort study.   PLoS One. 2015;10(4):e0125257. doi:10.1371/journal.pone.0125257PubMedGoogle Scholar
27.
Kim  TH , Yang  PS , Uhm  JS ,  et al.  CHA2DS2-VASc score (congestive heart failure, hypertension, age ≥75 [doubled], diabetes mellitus, prior stroke or transient ischemic attack [doubled], vascular disease, age 65-74, female) for stroke in Asian patients with atrial fibrillation: a Korean nationwide sample cohort study.   Stroke. 2017;48(6):1524-1530. doi:10.1161/STROKEAHA.117.016926PubMedGoogle ScholarCrossref
28.
Webster-Clark  M , Huang  TY , Hou  L , Toh  S .  Translating claims-based CHA2 DS2 -VaSc and HAS-BLED to ICD-10-CM: impacts of mapping strategies.   Pharmacoepidemiol Drug Saf. 2020;29(4):409-418. doi:10.1002/pds.4973PubMedGoogle ScholarCrossref
29.
Alonso  A , Agarwal  SK , Soliman  EZ ,  et al.  Incidence of atrial fibrillation in whites and African-Americans: the atherosclerosis risk in communities (ARIC) study.   Am Heart J. 2009;158(1):111-117. doi:10.1016/j.ahj.2009.05.010PubMedGoogle ScholarCrossref
30.
Haukoos  JS , Lewis  RJ .  The propensity score.   JAMA. 2015;314(15):1637-1638. doi:10.1001/jama.2015.13480PubMedGoogle ScholarCrossref
31.
Allison  PD .  Survival Analysis Using SAS: A Practical Guide. 2nd ed. SAS Institute; 2010.
32.
Kumar  S , Lim  E , Covic  A ,  et al.  Anticoagulation in concomitant chronic kidney disease and atrial fibrillation: JACC review topic of the week.   J Am Coll Cardiol. 2019;74(17):2204-2215. doi:10.1016/j.jacc.2019.08.1031PubMedGoogle ScholarCrossref
33.
Stürmer  T , Wyss  R , Glynn  RJ , Brookhart  MA .  Propensity scores for confounder adjustment when assessing the effects of medical interventions using nonexperimental study designs.   J Intern Med. 2014;275(6):570-580. doi:10.1111/joim.12197PubMedGoogle ScholarCrossref
34.
Haneuse  S , VanderWeele  TJ , Arterburn  D .  Using the E-value to assess the potential effect of unmeasured confounding in observational studies.   JAMA. 2019;321(6):602-603. doi:10.1001/jama.2018.21554PubMedGoogle ScholarCrossref
35.
Go  AS , Hylek  EM , Phillips  KA ,  et al.  Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the anticoagulation and risk factors in atrial fibrillation (ATRIA) study.   JAMA. 2001;285(18):2370-2375. doi:10.1001/jama.285.18.2370PubMedGoogle ScholarCrossref
36.
Lowenstern  A , Al-Khatib  SM , Sharan  L ,  et al.  Interventions for preventing thromboembolic events in patients with atrial fibrillation: a systematic review.   Ann Intern Med. 2018;169(11):774-787. doi:10.7326/M18-1523PubMedGoogle ScholarCrossref
37.
Eikelboom  JW , Connolly  SJ , Hart  RG ,  et al.  Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.   J Am Coll Cardiol. 2013;62(10):900-908. doi:10.1016/j.jacc.2013.05.042PubMedGoogle ScholarCrossref
38.
Huybrechts  KF , Gopalakrishnan  C , Franklin  JM ,  et al.  Claims data studies of direct oral anticoagulants can achieve balance in important clinical parameters only observable in electronic health records.   Clin Pharmacol Ther. 2019;105(4):979-993. doi:10.1002/cpt.1256PubMedGoogle ScholarCrossref
39.
Navar  AM , Roe  MT , White  JA ,  et al.  Medication discontinuation in the IMPROVE-IT trial.   Circ Cardiovasc Qual Outcomes. 2019;12(1):e005041. doi:10.1161/CIRCOUTCOMES.118.005041PubMedGoogle Scholar
40.
Kreutz  R , Persson  PB , Kubitza  D ,  et al.  Dissociation between the pharmacokinetics and pharmacodynamics of once-daily rivaroxaban and twice-daily apixaban: a randomized crossover study.   J Thromb Haemost. 2017;15(10):2017-2028. doi:10.1111/jth.13801PubMedGoogle ScholarCrossref
41.
Grześk  G , Rogowicz  D , Wołowiec  Ł ,  et al.  The clinical significance of drug-food interactions of direct oral anticoagulants.   Int J Mol Sci. 2021;22(16):8531. doi:10.3390/ijms22168531PubMedGoogle ScholarCrossref
42.
Bhaskar  R , Noon  J , O’Hara  BJ .  The errors in reporting Medicare coverage: a comparison of survey data and administrative records.   J Aging Health. 2019;31(10):1806-1829. doi:10.1177/0898264318797548PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close

My Saved Courses

You currently have no courses saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close